Loading insider details...
Beta
Latest Form 4 (Jan 21, 2026): Grant/Award of 19,547 QNCX shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jan 21, 2026 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 19,547 | n/a |
| Jun 6, 2025 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 27,000 | n/a |
| Jan 9, 2025 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 31,613 | n/a |
| Jun 8, 2024 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 27,000 | n/a |
| Aug 9, 2023 | Quince Therapeutics, Inc. (QNCX) | Purchase | 8,000 | $9.8K |
| May 26, 2023 | Quince Therapeutics, Inc. (QNCX) | Grant/Award | 27,000 | n/a |
| Jun 10, 2022 | Cortexyme, Inc. (CRTX) | Grant/Award | 27,000 | n/a |
| Oct 12, 2021 | Cortexyme, Inc. (CRTX) | Exercise/Conversion | 1,000 | $17.0K |
| Aug 18, 2021 | Cortexyme, Inc. (CRTX) | Exercise/Conversion | 6,000 | $102.0K |
| Jun 29, 2021 | Cortexyme, Inc. (CRTX) | Sale | 200 | $11.0K |